2025– date –

The second half of 2025’s “top 10” is where the industry’s center of gravity moved. The defining themes were clear: obesity drugs entering a second act (oralization + access design), ADCs solidifying as a pillar modality, China out-licen...

In 2025, innovation alone was not enough. Across biotech and pharma, policy, safety, manufacturing reliability, and reimbursement increasingly determined whether breakthroughs could scale in the real world. This first installment (Ranked...

Introduction: A Map of Aging × Cancer Is Starting to Emerge In this final article of the Expert Series, we step back to ask: Where is aging and cancer research heading over the next 10–20 years? How might these developments change clinic...

Introduction: Why “Young” Models Struggle to Capture “Old” Cancer Throughout this Expert Series we have discussed: Epigenetic clocks and ImAge as tools to visualize aging Tissue- and genotype-specific aging profiles How lymphoma and canc...

Introduction: The Gap Between Aging Biology and Everyday Oncology In earlier parts of this Expert Series, we have explored: Epigenetic clocks and ImAge as tools to quantify “how old” tissues and cells are Tissue- and genotype-specific pr...

Introduction: Adding Lifestyle and Environment to the Genetics–Aging Framework In previous parts of this Expert Series, we focused primarily on “internal” factors: Epigenetic clocks and ImAge as tools to visualize aging Tissue- and genot...

Introduction: Questioning the Dogma that “Aging = More Cancer” In previous parts of this Expert Series, we have discussed: Tools such as epigenetic clocks and ImAge to “visualize” aging Tissue-specific aging profiles and genetic backgrou...

Introduction: Why It Is Hard to Model Aging and Cancer Together In earlier parts of this Expert Series, we have discussed: Tools to visualize aging (epigenetic clocks, single-cell profiling, image-based metrics) Tissue-specific aging pro...

Introduction: Reproductive Aging as a Hub Between Women’s Aging and Cancer In Parts 1–3 of the Expert Series, we discussed: Tools to “visualize” aging (epigenetic clocks, single-cell profiles, image-based metrics) Tissue-specific aging p...

Introduction: Beyond “Aging → Cancer” to “Cancer → Aging” In the Introductory and earlier Expert Series articles, we mainly focused on the direction: Aging increases the risk of cancer Tissue- and genotype-specific aging patterns shape w...

Introduction: Aging Is Not Uniform Across the Body In Part 1 of the Expert Series, we focused on “making aging visible” through epigenetic clocks, single-cell analyses, and image-based metrics. We saw that people of the same chronologica...

Introduction: From the Introductory Series to the Expert Series In the Introductory Series (Parts 1–7), we approached the relationship between aging and cancer from multiple angles—historical, molecular, immunologic, organ-level, lifesty...

FDA approval summary On December 17, 2025, the U.S. Food and Drug Administration (FDA) granted regular approval to rucaparib (Rubraca, pharmaand GmbH) for adult patients with metastatic castration-resistant prostate cancer (mCRPC) associ...

Introduction: From Fragments to a Coherent Story In Parts 1–6, we approached the relationship between aging and cancer through several distinct lenses: Historical shifts in how aging and cancer are understood Molecular, genetic, and geno...

Introduction: Screening Is Not Just “The Earlier, the Better” In Parts 1–5, we explored the relationship between aging and cancer from multiple angles: molecular and genetic mechanisms, immune aging, organ-specific aging profiles, and li...

FDA approval summary On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with un...

Introduction: Deconstructing Risk Factors In Parts 1–4 of this series, we explored aging and cancer from several angles: Time and historical concepts Molecular and genetic mechanisms Immune aging and the tumor microenvironment Organ- and...

Introduction: Why Do Different Organs Develop Different Cancers with Age? In Parts 1–3, we looked at aging and cancer from the perspectives of time, molecular mechanisms, immunity, and the tumor microenvironment. We saw how aging reshape...

FDA approval summary On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adult patients with deleterious or suspected deleteriou...

Introduction: The Triangle of Aging, Cancer, and Immunity In Part 1, we explored why cancer is often described as a “disease of aging” and reviewed the historical and conceptual overlap between the hallmarks of aging and the hallmarks of...